Crispr Therapeutics
Crispr Therapeutics is a company to develop gene-based medicines based on CRISPR/Cas9 gene editing, co-founded by one of the co-inventors of CRISPR/Cas9, Emmanuelle Charpentier. Crispr Therapeutics is one of the few gene-editing startups that are using the new tool to pursue new treatments for sickle-cell anemia.[1]
As of November 2018, the Switzerland-based company had 127 full-time employees.[2] As of October 2018, it was the most valuable CRISPR company stock by market cap.[3]
In addition. the company is working on therapies for cystic fibrosis, and beta thalassemia.[4]
This article "Crispr Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Crispr Therapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- ↑ Mullin, Emily. "Sickle-Cell Patients See Hope in CRISPR". MIT Technology Review. 120 (6). pp. 11–13. Retrieved 2018-11-29.
- ↑ https://finance.yahoo.com/quote/CRSP/. Retrieved 29 Nov 2018. Missing or empty
|title=(help) - ↑ Chatsko, Maxx (2018-10-11). "Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September -- The Motley Fool". The Motley Fool. Retrieved 2018-11-29.
- ↑ "FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy". PMLive. 2018-10-12. Retrieved 2018-11-29.
